Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3CNS 3

Conditions

Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 6Lymphoma, Large B-Cell, Diffuse 5Hodgkin Disease 5Lymphoma, Follicular 4Lymphoma, B-Cell 4Leukemia, Lymphocytic, Chronic, B-Cell 3Gliosarcoma 3Glioblastoma 3Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Prolymphocytic, T-Cell 2Glioma 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Rasmussen subacute encephalitis 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Temozolomide 85Radiotherapy 51Bevacizumab 31Irinotecan 19Radiation 16Carmustine 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14O(6)-benzylguanine 11Chemotherapy, Adjuvant 11Carboplatin 9sargramostim 8Thalidomide 8Imatinib Mesylate 8Filgrastim 8Surgical Procedures, Operative 6Gene Expression Profiling 6Drug Therapy 6pembrolizumab 5aldesleukin 5Topotecan 5Radiotherapy, Intensity-Modulated 5Hydroxyurea 5Gefitinib 5Etoposide 5Sorafenib 4Immunohistochemistry 4Dasatinib 4Celecoxib 4Biopsy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Gliosarcoma × carmustine, poliferprosan 20 drug combination × Clear all
NCT00669669 2022-05-18

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT01186406 2019-02-15

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Duke University

Phase 2 Terminated
41 enrolled 9 charts
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

NCT00735436 2013-02-11

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

Duke University

Phase 2 Terminated
18 enrolled 11 charts
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡